AM Chemicals LLC entered into a license and supply agreement with Aligos Therapeutics whereby an exclusive license for the right to the use of specific GalNAc phosphoramidites for oligonucleotide therapeutic applications has been granted.

AM Chemicals LLC entered into an agreement with Glen Research whereby a license to commercialize (for research puropses only) selected GalNAc phosphoramidites and GalNAc solid supports for oligonucleotide synthesis and applications has been granted.

AM Chemicals LLC entered into an agreement with ChemGenes whereby a license to commercialize selected reagents for oligonucleotide synthesis has been granted.

AM Chemicals LLC entered into a license and supply agreement with Olix Pharmaceuticals whereby an exclusive license for the right to the use of selected GalNAc-modified phosphoramidites and solid supports for liver targeting strategies has been granted. 

02/11/2025

​Eli Lilly has signed a global licensing agreement with Olix Pharmaceuticals for the development and commercialization of an oligonucleotide compound (OLX75016) containing a GalNAc linker licensed from AM Chemicals.

​03/05/2024

An oligonucleotide compound (OLX75016) containing a GalNAc linker licensed from AM Chemicals is currently in Phase 1 clinical trials.

AM Chemicals LLC entered into a license agreement with GeneLink whereby a non-exclusive license for the right to manufacture, market and sell oligonucleotide conjugates using selected GalNAc-modified phosphoramidites and solid supports has been granted.